John A. Marcille

John A. Marcille

Lance Poulsen's lawyer would like everyone to know that his client has done nothing improper or illegal. Meanwhile, the company Poulsen founded and led until recently — National Century Financial Enterprises — operates under bankruptcy court protection.

Seems that Poulsen scoped out a niche industry in the 1990s. He heard the cries of hospitals and physician groups that said that third-party payers often took too long to pony up.

"Unable to wait weeks or months for insurance companies to pay claims, 60 ailing companies relied on cash from National Century to run their medical offices and facilities," USA Today reports.

That story focuses mostly on Poulsen, and contains a number of lessons.

Lesson 1: Background reviews are worth making. In 1984, Poulsen had been jailed for passing bad checks. In 1992, the IRS had hit him with a lien for $49,000 in back taxes. In the check-writing instance, the case was dismissed when he agreed to pay back victims. Within two years of the lien, he had also paid back the IRS. Some might consider these to be innocuous endings to bumps along a businessman's road. Some might consider them good reasons for not doing business with Poulsen. All should have been aware.

Lesson 2: Don't be intimidated. Poulsen, apparently, often won through intimidation. Michael McGee — a shareholder at PhyAmerica, a medical services company, had asked some skeptical questions about financing — and, as a result, had been on the receiving end of Poulsen's tactics. McGee sued, settling last year for $4 million. "I wasn't going to sit by and let this happen to me or other investors."

Lesson 3: Thank goodness for whistle-blowers. Seems as though anonymous letters sent to bond-rating agencies last year helped to build the case against Poulsen.

Lesson 4: This must have been so obvious that no one bothered to spell it out to the managed care industry back in the beginning: Do the right thing --in this case, pay people on time. If health plans had just done that, then Lance Poulsen, who did nothing illegal or improper according to his lawyer, would have missed his opportunity, and a lot of other people would be better off today.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.